ESMO 2017: Atezolizumab in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma: Post-Progression Outcomes from the Phase 2 IMvigor210 Study

Madrid, Spain (UroToday.com) At today’s poster discussion session at ESMO 2017, Dr. Necchi and colleagues presented results from their study assessing atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma. Certainly, there are few adequate treatment options for metastatic urothelial carcinoma, which portends a poor overall survival (OS).

ESMO 2017: Epithelial-mesenchymal transition, T cell infiltration, and outcomes with nivolumab in urothelial cancer

Madrid, Spain (UroToday.com) Dr. Galsky and colleagues presented their work at ESMO 2017, assessing epithelial-mesenchymal transition (EMT), T cell differentiation, and outcomes for patients with urothelial cancer treated with nivolumab. Certainly, the presence of tumor infiltrating lymphocytes has been associated with a higher objective response rate (ORR) to PD-1/PD-L1 blockade.

ESMO 2017: Pembrolizumab versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer: mature results from the phase 3 KEYNOTE-045 trial

Madrid, Spain (UroToday.com) Dr. De Wit and colleagues presented their late-breaking abstract this afternoon at ESMO 2017, reporting mature results from the phase III KEYNOTE-045 trial assessing pembrolizumab vs chemotherapy for patients with recurrent, advanced urothelial cancer. In the initial report of this trial, pembrolizumab was associated with significantly longer overall survival (OS) compared to either paclitaxel, docetaxel, or vinflunine chemotherapy (median 10.3 vs 7.4 months; HR 0.73, 95%CI 0.59-0.91) [1]. The objective of the current study was to present mature results from this phase III trial.

ESMO 2017: KEYNOTE-045: Pembrolizumab vs Individual Investigator’s Choice of Chemotherapy in Recurrent, Advanced Urothelial Cancer

Madrid, Spain (UroToday.com)- Dr. Petrylak and colleagues presented their subgroup analysis of KEYNOTE-045 assessing pembrolizumab vs individual chemotherapy agents for patients with recurrent, advanced urothelial carcinoma. In the phase III KEYNOTE-045 study, overall survival (OS) was significantly longer with pembrolizumab vs investigator’s choice of chemotherapy regimen (median 10.3 vs 7.4 months; HR 0.73, 95%CI 0.59-0.91) [1]. The objective of this post-hoc analysis was to assess the outcomes of patients treated with pembrolizumab to the individual agents in the chemotherapy arm. 

ESMO 2017: Impact of Tumor Mutation Burden on Nivolumab Efficacy in Second-Line Urothelial Carcinoma Patients: Exploratory Analysis of the Phase II CheckMate 275 Study

Madrid, Spain (UroToday.com) Dr. Galsky and colleagues presented their results on the impact of tumor mutation burden on nivolumab efficacy as a second-line agent in patients with urothelial carcinoma.

ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer

Madrid, Spain (UroToday.com) Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE trial presented today at the ESMO 2017 Congress in Madrid (1) to be published in The Lancet (2).

ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer

Madrid, Spain (UroToday.com) Mature results from the KEYNOTE-045 trial to be presented today at the ESMO 2017 Congress in Madrid (1) have confirmed significantly longer survival in patients with advanced urothelial cancer who receive the checkpoint inhibitor pembrolizumab after initial chemotherapy, compared to an alternative chemotherapy regimen.
Page 3 of 3
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe